Novo Nordisk Brings Wegovy Pill to UK as 2 Million Americans Already Use It
Updated
Updated · LBC · May 28
Novo Nordisk Brings Wegovy Pill to UK as 2 Million Americans Already Use It
3 articles · Updated · LBC · May 28
Summary
Novo Nordisk’s Wegovy weight-loss pill is expected to reach UK patients in the coming months, extending obesity treatment beyond injections already widely used privately and on the NHS.
More than 2 million Americans have been prescribed the pill since its US rollout earlier this year, suggesting strong demand for an oral option that avoids needles, refrigeration and sharps disposal.
The tablet uses the same GLP-1 mechanism as Wegovy injections and carries broadly similar side effects, which studies say are usually mild and ease as patients adjust.
About 2.5 million people in the UK already access weight-loss injections, and obesity is estimated to cost the country more than £100 billion a year, giving the launch wider health and economic significance.